A recent clinical trial for a drug candidate for rectal cancer has shown dramatic results, with complete remission seen in all participants.
A first
dealing with cancer drug Jemperlimade by GSKthis involved 13 participants with rectal cancer locally advanced. The results are incredibly encouraging, especially considering that the participants did not have to undergo radiation therapy, chemotherapy, or any other type of cancer procedure.
” What is truly remarkable is that this is the first time to my knowledge, in the field of solid tumor oncology, that a 100% complete answer has been obtained “, highlighted Luis Diazhead of the solid tumor oncology division at Memorial Sloan Kettering and co-author of the new study, published in The New England Journal of Medicine.
According to the team, the tumors of all the participants had a rare genetic mutation called “ base mismatch repair system deficiency (MRD), implying that their cells were less prone to repair DNA errors, known to promote the development of cancer. Eight of them also had syndrome Lyncha genetic disease with similar effects.
Certain immunotherapy drugs such as Jemperli are believed to have potential effects against cancers developed by such conditions, as they alter the way the immune system interacts with cells whose DNA strands contain errors, allowing the patient’s body to detect and target the tumor.
No recurrence observed within six months of treatment
The current study also drew on previous research on treating patients with a similar profile but with metastatic tumors, with a compound named Keytruda. Based on these results, the team wanted to determine if immunotherapeutic drugs could be used even before their tumors spread.
As promising as it is, it should be remembered that the new trial concerns a limited sample of subjects, and that the results are not definitive: although no tumor reappeared in the various patients in the six months following the treatment, these can only be declared completely cured after a period of remission lasting several years.
” Pointing to the possibility of treating certain types of cancer with far fewer side effects than other treatment options, these results give cause for optimism. », comments Hanna K. Sanoffoncologist at Lineberger Comprehensive Cancer Center of the’university of north carolina. ” However, we will still have to wait to find out if such a treatment can replace our current curative therapeutic approach.. »
[related_posts_by_tax taxonomies=”post_tag”]
The post Experimental drug eradicates common cancer in all patients appeared first on Gamingsym.